Based on the Tatva Chintan Pharma Chem Limited stock forecast from 2 analysts, the average analyst target price for Tatva Chintan Pharma Chem Limited is INR 842.33 over the next 12 months. Tatva Chintan Pharma Chem Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Tatva Chintan Pharma Chem Limited is Slightly Bearish, which is based on 5 positive signals and 10 negative signals. At the last closing, Tatva Chintan Pharma Chem Limited’s stock price was INR 920.55. Tatva Chintan Pharma Chem Limited’s stock price has changed by +20.29% over the past week, +23.98% over the past month and -17.81% over the last year.
No recent analyst target price found for Tatva Chintan Pharma Chem Limited
No recent average analyst rating found for Tatva Chintan Pharma Chem Limited
Company Overview Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batteries; and pharmaceutical and agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. The company serves automotive, refinery, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India. Read Less
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor and zinc ion batterie...Read More
Based on ratings from 2 analysts Tatva Chintan Pharma Chem Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, 1 sell and 1 hold ratings.
TATVA:NSE stock's dividend yield is 0.27%.
Our analysis grades TATVA:NSE stock's dividend yield at F. This means that TATVA:NSE stock's dividend yield is above 28% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this TATVA:NSE may be a poor dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for TATVA:NSE is INR 842.33 over the next 12 months. The maximum analyst target price is INR 1000 while the minimum anlayst target price is INR 761.
TATVA:NSE stock's Price/Earning ratio is 120.50.
Our analysis grades TATVA:NSE stock's Price / Earning ratio at F. This means that TATVA:NSE stock's Price/Earning ratio is above 93% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this TATVA:NSE may be a overvalued for its sector.
The last closing price of TATVA:NSE's stock was INR 920.55.
The most recent market capitalization for TATVA:NSE is INR 17.28B.
Based on targets from 2 analysts, the average taret price for TATVA:NSE is projected at INR 842.33 over the next 12 months.
This means that TATVA:NSE's stock price may go down by -8.50% over the next 12 months.
We can't find any ETFs which contains Tatva Chintan Pharma Chem Limited's stock.
As per our most recent records Tatva Chintan Pharma Chem Limited has 0 Employees.
Tatva Chintan Pharma Chem Limited's registered address is Plot No. 353, Vadodara, India, 390010.
You can get more information about it from Tatva Chintan Pharma Chem Limited's website at https://www.tatvachintan.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Based on ratings from 2 analysts Tatva Chintan Pharma Chem Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, 1 sell and 1 hold ratings.
TATVA:NSE stock's dividend yield is 0.27%.
Our analysis grades TATVA:NSE stock's dividend yield at F. This means that TATVA:NSE stock's dividend yield is above 28% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this TATVA:NSE may be a poor dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for TATVA:NSE is INR 842.33 over the next 12 months. The maximum analyst target price is INR 1000 while the minimum anlayst target price is INR 761.
TATVA:NSE stock's Price/Earning ratio is 120.50.
Our analysis grades TATVA:NSE stock's Price / Earning ratio at F. This means that TATVA:NSE stock's Price/Earning ratio is above 93% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this TATVA:NSE may be a overvalued for its sector.
The last closing price of TATVA:NSE's stock was INR 920.55.
The most recent market capitalization for TATVA:NSE is INR 17.28B.
Based on targets from 2 analysts, the average taret price for TATVA:NSE is projected at INR 842.33 over the next 12 months.
This means that TATVA:NSE's stock price may go down by -8.50% over the next 12 months.
We can't find any ETFs which contains Tatva Chintan Pharma Chem Limited's stock.
As per our most recent records Tatva Chintan Pharma Chem Limited has 0 Employees.
Tatva Chintan Pharma Chem Limited's registered address is Plot No. 353, Vadodara, India, 390010.
You can get more information about it from Tatva Chintan Pharma Chem Limited's website at https://www.tatvachintan.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TATVA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
